Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Technology
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Visual Stories
  • Reviews
  • Phone Reviews
  • Fitness Bands Reviews
  • Speakers Reviews
  • Find Cricket Statistics
Hindi
More
In the news
Samsung
Elon Musk
Apple
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Technology
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Visual Stories
Reviews
Phone Reviews
Fitness Bands Reviews
Speakers Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / Technology News / COVID-19 vaccine offers minimal protection to organ transplant recipients: Study
Technology

COVID-19 vaccine offers minimal protection to organ transplant recipients: Study

COVID-19 vaccine offers minimal protection to organ transplant recipients: Study
Written by Sneha Das
(Sourced from PTI)
May 10, 2021, 04:47 pm 3 min read
COVID-19 vaccine offers minimal protection to organ transplant recipients: Study
Organ transplant recipients need to follow protocols even after vaccination

Although two doses of a COVID-19 vaccine confer protection for people who have received solid organ transplants, it's not enough to enable them to dispense with masks, physical distancing, and safety measures, a study said. It's a follow-up study to an earlier one in which researchers reported, 17 percent of participating transplant recipients produced sufficient antibodies after one dose of a two-dose vaccine regimen.

Second shot
Antibody levels increased, but not in enough transplant recipients

"There was an increase in those with detectable antibodies after the second shot," said lead author Brian Boyarsky from the Johns Hopkins University School of Medicine in the US. "However, the number of transplant recipients in our second study whose antibody levels reached high enough levels to ward off infection was still well below than in people with healthy immune systems," Boyarsky said.

COVID-19 safety protocols
Transplant recipients should continue to practice COVID-19 safety precautions

"Based on our findings, we recommend that transplant recipients and other immunocompromised patients continue to practice strict COVID-19 safety precautions, even after their vaccination," Boyarsky said. The researchers noted that the people who receive solid organ transplants, such as hearts, lungs, and kidneys, often must take drugs to suppress their immune systems and prevent rejection.

Quote
Some drugs affect transplant recipient's ability to make antibodies

"Such regimens may interfere with a transplant recipient's ability to make antibodies to foreign substances, including the protective ones produced in response to vaccines," they said.

Two-dose regimen
This immunogenic response after second dose was evaluated

The latest study, published in the Journal of the American Medical Association (JAMA), evaluated this immunogenic response following the second dose of either of the two mRNA vaccines - made by Moderna and Pfizer-BioNTech - for 658 transplant recipients, none of whom had a prior diagnosis of COVID-19. The participants completed their two-dose regimen between December 16, 2020, and March 13, 2021.

Information
98 of 658 study participants had detectable antibodies

The researchers found that 98 of 658 study participants - 15 percent - had detectable antibodies to SARS-CoV-2 at 21 days after the first dose. This was comparable to 17 percent reported in the March study looking at immune response after only one vaccine dose.

Antibodies
Here are other figures regarding antibodies after vaccination

"At 29 days following the second dose, the number of participants with detectable antibodies rose to 357 out of 658 - 54 percent," the researchers said. "After both vaccine doses were administered, 301 out of 658 participants - 46 percent - had no detectable antibody at all while 259 - 39 percent - only produced antibodies after the second shot," they said.

Antibody response
Younger age group most likely to develop an antibody response

The researchers also found that among the participants, the most likely to develop an antibody response were mostly younger, those who did not take the immunosuppressive regimens including the anti-metabolite drugs and also received the Moderna vaccine. "These were similar to all the associations that were seen in the March single-dose study," the researchers said.

Quote
Wrong to assume two vaccine doses guarantee sufficient immunity

"Given these observations, transplant recipients should not assume that two vaccine doses guarantee sufficient immunity against SARS-CoV-2 any more than it did after just one dose," said study co-author Dorry Segev, from the Johns Hopkins University School of Medicine.

Share this timeline
Facebook
Whatsapp
Twitter
Linkedin
Sneha Das <br/><i>(Sourced from PTI)</i>
Sneha Das
(Sourced from PTI)
Twitter
Sneha Das is a lifestyle writer at NewsBytes. She had started her career with NewsBytes and her work has focused on national and lifestyle news. She has previously worked as an intern with The Sakal Times, The Logical Indian, and 91.9 Friends FM. She has a Bachelor's degree in Journalism and Mass Communication from the University of Calcutta.
Latest
Vaccine
Research
COVID-19
Related
Latest
Rivaling Amazon, Walmart-backed PhonePe to buy two wealth management firms
Rivaling Amazon, Walmart-backed PhonePe to buy two wealth management firms Business
Succession law: Centre supports provision prioritizing husband's kin
Succession law: Centre supports provision prioritizing husband's kin India
Delhi Lieutenant Governor Anil Baijal resigns citing 'personal reasons'
Delhi Lieutenant Governor Anil Baijal resigns citing 'personal reasons' Politics
'Tezaab': Madhuri Dixit, Anil Kapoor's classic gearing up for remake
'Tezaab': Madhuri Dixit, Anil Kapoor's classic gearing up for remake Entertainment
iQOO Neo 6 to launch in India on May 31
iQOO Neo 6 to launch in India on May 31 Technology
Vaccine
COVID-19: India logs 2,487 fresh cases, 13 more fatalities
COVID-19: India logs 2,487 fresh cases, 13 more fatalities India
COVID-19: India logs 2,858 fresh cases, 11 more fatalities
COVID-19: India logs 2,858 fresh cases, 11 more fatalities India
India: Phase-2 trials of world's first one-shot pneumococcal vaccine soon
India: Phase-2 trials of world's first one-shot pneumococcal vaccine soon India
India inching closer to launching its first dengue vaccine
India inching closer to launching its first dengue vaccine India
National Vaccination Day 2022: Know theme, history, significance
National Vaccination Day 2022: Know theme, history, significance Lifestyle
More News
Research
New universal coronavirus vaccine may help prevent future pandemics
New universal coronavirus vaccine may help prevent future pandemics Technology
Are your dreams telling you something?
Are your dreams telling you something? Lifestyle
This 3D-printable 'living ink' can capture toxins, release anti-cancer drugs
This 3D-printable 'living ink' can capture toxins, release anti-cancer drugs Technology
China overtakes US as world's richest; experts sound caution
China overtakes US as world's richest; experts sound caution World
COVID-19 cuts India's life expectancy by 2 years, says study
COVID-19 cuts India's life expectancy by 2 years, says study India
More News
COVID-19
COVID-19: India reports 1,829 new cases, 33 more fatalities
COVID-19: India reports 1,829 new cases, 33 more fatalities India
COVID-19: India reports 1,569 new cases, 19 more deaths
COVID-19: India reports 1,569 new cases, 19 more deaths India
COVID-19: India logs 2,202 new cases; 27 more deaths
COVID-19: India logs 2,202 new cases; 27 more deaths India
North Korea: 8,20,620 fresh COVID-19 cases in just 3 days
North Korea: 8,20,620 fresh COVID-19 cases in just 3 days World
North Korea reports 6 COVID-19 deaths, isolates 1,87,800 people
North Korea reports 6 COVID-19 deaths, isolates 1,87,800 people World
More News
Related
'Cautious optimism' after initial Omicron studies; here's what we know
'Cautious optimism' after initial Omicron studies; here's what we know Technology
US: Pfizer-BioNTech COVID-19 vaccine officially granted full approval by FDA
US: Pfizer-BioNTech COVID-19 vaccine officially granted full approval by FDA World
Pfizer-BioNTech COVID-19 vaccine to get US-FDA's full approval next week
Pfizer-BioNTech COVID-19 vaccine to get US-FDA's full approval next week World
India may buy 50mn Pfizer COVID-19 vaccine doses: Details here
India may buy 50mn Pfizer COVID-19 vaccine doses: Details here India
Next News Article
Next News Article

Love Technology news?

Subscribe to stay updated.

Science Thumbnail
India News Business News World News Politics News Sports News Technology News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Mukesh Ambani Indian Premier League (IPL) Karnataka Samsung Xiaomi West Bengal
Bihar Virat Kohli Rohit Sharma Haryana Narendra Modi Arvind Kejriwal Tamil Nadu Gujarat Yogi Adityanath YouTube
Instagram Hollywood News Uttar Pradesh Kerala Netflix Bollywood News Mamata Banerjee Maruti Suzuki Rahul Gandhi Elon Musk
Shah Rukh Khan Chelsea FC OPPO Akhilesh Yadav Indian Cricket Team Apple Manchester United Salman Khan Cryptocurrency OnePlus
Amitabh Bachchan ICC Women's World Cup Vivo India vs Sri Lanka
About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive IPL 2022 Schedule IPL 2022 Points Table Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2022